Login to Your Account



American Society of Clinical Oncology

Nexavar Boosts Survival In Liver Cancer By 44 Percent

By Jennifer Boggs


Tuesday, June 5, 2007
Onyx Pharmaceuticals Inc. and partner Bayer Healthcare Pharmaceuticals Inc. reported detailed results from their positive Phase III trial of Nexavar (sorafenib) in liver cancer, which has emerged as one of the biggest headlines at this year's American Society of Clinical Oncology meeting in Chicago. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription